Adverum Biotechnologies Stock (NASDAQ:ADVM), Analyst Ratings, Price Targets, Predictions

The latest price target for Adverum Biotechnologies (NASDAQ: ADVM) was reported by HC Wainwright & Co. on May 10, 2024. The analyst firm set a price target for $30.00 expecting ADVM to rise to within 12 months (a possible 222.58% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Adverum Biotechnologies (NASDAQ: ADVM) was provided by HC Wainwright & Co., and Adverum Biotechnologies reiterated their buy rating.

The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.

The last downgrade for Adverum Biotechnologies Inc happened on July 23, 2021 when Cantor Fitzgerald changed their price target from $23 to $3 for Adverum Biotechnologies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.

While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a reiterated with a price target of $0.00 to $30.00. The current price Adverum Biotechnologies (ADVM) is trading at is $9.30, which is within the analyst’s predicted range.